Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Boehringer Ingelheim
McKinsey
Colorcon
Mallinckrodt

Last Updated: June 28, 2022

PHEXXI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Phexxi, and when can generic versions of Phexxi launch?

Phexxi is a drug marketed by Evofem Inc and is included in one NDA. There are two patents protecting this drug.

This drug has forty-three patent family members in twenty-two countries.

The generic ingredient in PHEXXI is citric acid; lactic acid; potassium bitartrate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the citric acid; lactic acid; potassium bitartrate profile page.

DrugPatentWatch® Generic Entry Outlook for Phexxi

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 22, 2023. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for PHEXXI
International Patents:43
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
Formulation / Manufacturing:see details
Drug Prices: Drug price information for PHEXXI
What excipients (inactive ingredients) are in PHEXXI?PHEXXI excipients list
DailyMed Link:PHEXXI at DailyMed
Drug patent expirations by year for PHEXXI
Drug Prices for PHEXXI

See drug prices for PHEXXI

DrugPatentWatch® Estimated Generic Entry Opportunity Date for PHEXXI
Generic Entry Date for PHEXXI*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT
NDA:
Dosage:
GEL;VAGINAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PHEXXI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ParexelPhase 3
Evofem Inc.Phase 3
Health DecisionsPhase 3

See all PHEXXI clinical trials

US Patents and Regulatory Information for PHEXXI

PHEXXI is protected by two US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PHEXXI is See Plans and Pricing.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting PHEXXI

Compositions and methods for enhancing the efficacy of contraceptive microbicides
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY

Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting PHEXXI

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Evofem Inc PHEXXI citric acid; lactic acid; potassium bitartrate GEL;VAGINAL 208352-001 May 22, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Evofem Inc PHEXXI citric acid; lactic acid; potassium bitartrate GEL;VAGINAL 208352-001 May 22, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Evofem Inc PHEXXI citric acid; lactic acid; potassium bitartrate GEL;VAGINAL 208352-001 May 22, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for PHEXXI

See the table below for patents covering PHEXXI around the world.

Country Patent Number Title Estimated Expiration
Mexico 365905 COMPOSICIONES Y MÉTODOS PARA MEJORAR LA EFICACIA DE MICROBICIDAS ANTICONCEPTIVOS. (COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES.) See Plans and Pricing
Israel 151649 תכשרים ושיטות ללכידת והשבתת חידקים פתוגניים וספרמטוזוה (Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa) See Plans and Pricing
Singapore 11201408243V COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES See Plans and Pricing
European Patent Office 1263411 Compositions et leurs utilisation permettant de piéger et d'inactiver les microbes pathogènes et les spermatozoïdes (Compositions and use thereof for trapping and inactivating pathogenic microbes and spermatozoa) See Plans and Pricing
South Korea 102062599 See Plans and Pricing
Russian Federation 2274442 КОМПОЗИЦИИ И СПОСОБЫ УЛАВЛИВАНИЯ И ИНАКТИВАЦИИ ПАТОГЕННЫХ МИКРООРГАНИЗМОВ И СПЕРМАТОЗОИДОВ (COMPOSITIONS AND METHODS FOR ENTRAPPING AND INACTIVATION OF PATHOGENIC MICROORGANISMS AND SPERMATOZOIDS) See Plans and Pricing
Eurasian Patent Organization 201590008 КОМПОЗИЦИИ И СПОСОБЫ ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ БАКТЕРИЦИДНЫХ СРЕДСТВ КОНТРАЦЕПЦИИ See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Johnson and Johnson
Mallinckrodt
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.